Compare SKYH & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYH | CANF |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.4M | 6.7M |
| IPO Year | 2020 | 2011 |
| Metric | SKYH | CANF |
|---|---|---|
| Price | $10.10 | $2.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $13.13 | ★ $50.00 |
| AVG Volume (30 Days) | 127.8K | ★ 195.3K |
| Earning Date | 05-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,540,000.00 | N/A |
| Revenue This Year | $78.89 | $2,715,455.50 |
| Revenue Next Year | $73.15 | $101.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 86.57 | N/A |
| 52 Week Low | $8.22 | $0.17 |
| 52 Week High | $11.70 | $10.40 |
| Indicator | SKYH | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 42.16 | 33.18 |
| Support Level | $10.01 | $0.17 |
| Resistance Level | $10.16 | $3.59 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 17.28 | 12.50 |
Sky Harbour Group Corp is an aviation infrastructure company focused on building the first nationwide network of Home Base Operator (HBO) campuses designed exclusively for business aircraft. The company develops, leases, and manages general aviation hangars across the United States, targeting airfields in markets with aircraft populations and high hangar demand. Its HBS campuses include private hangars and offer a range of services tailored to aircraft owners operating from these facilities. The majority of the company's revenue is derived from the leasing of home-based aircraft hangars and through services and products ancillary to its leasing activities.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.